Genetic testing discovers cancer gene

Washington: According to a recent study, genetic testing can play a substantial role in medical management by uncovering changes in genes that are associated with an increased risk for hereditary cancers. The conclusion of the research is based on a study that reviewed genetic testing results from 1.45 million individuals and found that nearly 25 per cent of “variants of uncertain significance” were subsequently reclassified — sometimes as less likely to be associated with cancer, sometimes as more likely. When variations from the norm are discovered in a gene, the variants are classified as “benign,” “likely benign,” “variant of uncertain significance,” “likely pathogenic,” or “pathogenic.” Dr. Theo Ross, senior author of the study, said, “If a variant is reclassified to being pathogenic, then it matters to the patient.” “For example, if they have a broken Lynch syndrome gene, then they need different care from their doctor such as having colonoscopies at an earlier age or more frequently, sometimes as often as every year. Or, if they have a broken BRCA gene, they may want to have prophylactic surgery or add MRI scans to their mammogram screening program,” he explained. Even a reclassification from “variant of uncertain significance” to “benign” can be important to a patient, providing them with peace of mind. The typical gene contains about 27,000 base pairs. A large number of base pairs in each gene means there are myriad potential variations and there are many gaps in knowledge about the significance of individual variations.